AlloVir Dirección
Dirección controles de criterios 3/4
El CEO de AlloVir es Diana Brainard , nombrado en May 2021, tiene una permanencia de 3.5 años. compensación anual total es $6.06M, compuesta por 10.3% salario y 89.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de $253.97K. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 4.3 años, respectivamente.
Información clave
Diana Brainard
Chief Executive Officer (CEO)
US$6.1m
Compensación total
Porcentaje del salario del CEO | 10.3% |
Permanencia del CEO | 3.5yrs |
Participación del CEO | 0.3% |
Permanencia media de la dirección | 5.8yrs |
Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely
Oct 29Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Jul 13We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04AlloVir EPS misses by $0.28
Nov 10Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$140m |
Mar 31 2024 | n/a | n/a | -US$180m |
Dec 31 2023 | US$6m | US$623k | -US$190m |
Sep 30 2023 | n/a | n/a | -US$169m |
Jun 30 2023 | n/a | n/a | -US$167m |
Mar 31 2023 | n/a | n/a | -US$166m |
Dec 31 2022 | US$9m | US$605k | -US$169m |
Sep 30 2022 | n/a | n/a | -US$189m |
Jun 30 2022 | n/a | n/a | -US$192m |
Mar 31 2022 | n/a | n/a | -US$185m |
Dec 31 2021 | US$15m | US$365k | -US$172m |
Sep 30 2021 | n/a | n/a | -US$139m |
Jun 30 2021 | n/a | n/a | -US$117m |
Mar 31 2021 | n/a | n/a | -US$91m |
Dec 31 2020 | US$597k | n/a | -US$70m |
Compensación vs. Mercado: La compensación total de Diana($USD6.06M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD648.89K).
Compensación vs. Ingresos: La compensación de Diana ha sido consistente con los resultados de la empresa en el último año.
CEO
Diana Brainard (52 yo)
3.5yrs
Permanencia
US$6,056,943
Compensación
Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Executive Chairman of the Board | 6.2yrs | US$347.00k | 2.46% $ 2.1m | |
CEO & Director | 3.5yrs | US$6.06m | 0.30% $ 254.0k | |
President | 5.8yrs | US$2.94m | 0.85% $ 719.6k | |
General Counsel & Secretary | 5.8yrs | US$1.89m | 0.38% $ 316.9k | |
Chief Accounting Officer | 5.8yrs | sin datos | 0.061% $ 51.0k | |
Chief Scientific Officer | 11.8yrs | sin datos | sin datos | |
Chief Commercial Officer | 1.4yrs | sin datos | sin datos |
5.8yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALVR es experimentado (5.8 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Executive Chairman of the Board | 6.2yrs | US$347.00k | 2.46% $ 2.1m | |
CEO & Director | 4.3yrs | US$6.06m | 0.30% $ 254.0k | |
President | 5.8yrs | US$2.94m | 0.85% $ 719.6k | |
Member of the Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
Independent Non-Executive Director | 12.8yrs | US$196.28k | 0.20% $ 169.2k | |
Independent Non-Executive Director | 4.3yrs | US$211.78k | 0.066% $ 55.6k | |
Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
Independent Non-Executive Director | 5.5yrs | US$209.28k | 8.67% $ 7.3m | |
Independent Director | 2.7yrs | US$200.73k | 0.031% $ 25.9k | |
Non-Executive Director | 10.8yrs | US$187.00k | 2.08% $ 1.8m |
4.3yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de ALVR se considera experimentada (4.3 años de antigüedad promedio).